Selecta Biosciences, Inc. (NASDAQ:SELB) has received an average rating of “Buy” from the six analysts that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $29.00.

Several brokerages have recently commented on SELB. Canaccord Genuity set a $25.00 price target on Selecta Biosciences and gave the company a “buy” rating in a research note on Wednesday, July 26th. Zacks Investment Research lowered Selecta Biosciences from a “hold” rating to a “sell” rating in a research note on Wednesday, August 16th. Finally, ValuEngine lowered Selecta Biosciences from a “hold” rating to a “sell” rating in a research note on Tuesday, September 26th.

In other Selecta Biosciences news, CFO David Siewers sold 16,424 shares of the company’s stock in a transaction dated Wednesday, September 20th. The stock was sold at an average price of $20.00, for a total transaction of $328,480.00. Following the sale, the chief financial officer now owns 2,194 shares in the company, valued at approximately $43,880. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Amir Nashat sold 147,187 shares of the company’s stock in a transaction dated Thursday, September 21st. The stock was sold at an average price of $19.91, for a total value of $2,930,493.17. The disclosure for this sale can be found here. Insiders sold a total of 355,658 shares of company stock worth $6,955,732 in the last quarter. Company insiders own 41.90% of the company’s stock.

A number of hedge funds and other institutional investors have recently modified their holdings of SELB. Vivo Capital LLC purchased a new stake in Selecta Biosciences during the 2nd quarter worth about $22,227,000. Vanguard Group Inc. increased its holdings in Selecta Biosciences by 175.5% during the 2nd quarter. Vanguard Group Inc. now owns 217,634 shares of the company’s stock worth $4,322,000 after purchasing an additional 138,646 shares during the period. JPMorgan Chase & Co. increased its holdings in Selecta Biosciences by 46.8% during the 2nd quarter. JPMorgan Chase & Co. now owns 358,846 shares of the company’s stock worth $7,126,000 after purchasing an additional 114,477 shares during the period. Candriam Luxembourg S.C.A. increased its holdings in Selecta Biosciences by 306.5% during the 2nd quarter. Candriam Luxembourg S.C.A. now owns 126,000 shares of the company’s stock worth $2,502,000 after purchasing an additional 95,000 shares during the period. Finally, State Street Corp increased its holdings in Selecta Biosciences by 118.5% during the 2nd quarter. State Street Corp now owns 152,430 shares of the company’s stock worth $3,027,000 after purchasing an additional 82,665 shares during the period. Institutional investors own 53.53% of the company’s stock.

Selecta Biosciences (NASDAQ:SELB) last released its quarterly earnings data on Friday, August 11th. The company reported ($0.85) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.86) by $0.01. The company had revenue of $0.03 million for the quarter. Selecta Biosciences had a negative return on equity of 88.31% and a negative net margin of 1,277.76%.

TRADEMARK VIOLATION WARNING: “Selecta Biosciences, Inc. (SELB) Receives Average Recommendation of “Buy” from Analysts” was published by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark legislation. The legal version of this report can be accessed at https://www.americanbankingnews.com/2017/11/02/selecta-biosciences-inc-selb-receives-average-recommendation-of-buy-from-analysts.html.

Selecta Biosciences Company Profile

Selecta Biosciences, Inc is a clinical-stage biopharmaceutical company. The Company using its synthetic vaccine particle (SVP) technology to discover and develop targeted therapies that are designed to modulate the immune system to treat rare and serious diseases. The Company is engaged in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases.

Receive News & Ratings for Selecta Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.